Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Cincinnati Wellness Review.
Press releases published on June 3, 2025
Antioch University Approved to Launch Graduate Nursing Programs Nationwide
EIN Presswire
·
June 3, 2025
Programs to Be Delivered Online, Expanding Access for Working Professionals YELLOW SPRINGS, OH, UNITED STATES, June 3, 2025 /EINPresswire.com/ -- Antioch University is proud to announce that the Higher Learning Commission’s Institutional Actions …
Erney Tourney Charity Golf Outing Supports AngelWorks Foundation for Childhood Cancer Care and Research
EIN Presswire
·
June 3, 2025
Erney Tourney Charity Golf Outing raiseess funds for the AngelWorks Foundation and its mission to assist children battling cancer. COLUMBUS, OH, UNITED STATES, June 3, 2025 /EINPresswire.com/ -- The 14th Annual Erney Tourney Charity Golf Outing returns …
122 Years of Cleveland Legacy, A Future of Innovation: VNA of Ohio Joins h/care
EIN Presswire
·
June 3, 2025
VNA of Ohio, a Cleveland-based 122 year old home care institution founded by 12 brave women has been acquired by h/care CLEVELAND, OH, UNITED STATES, June 3, 2025 /EINPresswire.com/ -- The Visiting Nurse Association of Ohio (VNA of Ohio), a cornerstone …
Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer
GlobeNewswire
·
June 3, 2025
TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the pricing and early acceptance results of its previously announced tender offers (the “Offers”) to purchase for cash …
Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program
GlobeNewswire
·
June 3, 2025
Recently disclosed clinical cohort data from high (1x1015 total vg) and low dose (5.7x1014 total vg) TSHA-102 from REVEAL adolescent/adult and pediatric Phase 1/2 trials Caregiver research regarding gain/regain of developmental milestones supporting …
Bierman Autism Centers Expands Access With New Columbus Clinic Opening Fall 2025
EIN Presswire
·
June 3, 2025
Bierman opens fourth Ohio clinic in Columbus fall 2025, expanding ABA, speech …
Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire
·
June 3, 2025
NOVATO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today …
Fennec Announces Results of Annual Meeting
GlobeNewswire
·
June 3, 2025
RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 25, 2025 were elected as directors of …
Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08
GlobeNewswire
·
June 3, 2025
NEW YORK, June 03, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in virtual care, today announced that it issued inducement awards to two new employees. Effective June 1, 2025, in connection with commencing employment, two …
DBV Technologies publie un amendement à son Document d’enregistrement universel 2024
GlobeNewswire
·
June 3, 2025
Châtillon, France, le 3 juin 2025 DBV Technologies publie un amendement à son Document d’enregistrement universel 2024 DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market : DBVT), (la « Société »), société biopharmaceutique en …
DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document
GlobeNewswire
·
June 3, 2025
Châtillon, France, June 03, 2025 DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company …
Yhdysvaltain lääkeviranomainen FDA hyväksyi kolmannen käyttöaiheen darolutamidille edennyttä eturauhassyöpää sairastavien potilaiden hoidossa
GlobeNewswire
·
June 3, 2025
ORION OYJ LEHDISTÖTIEDOTE 3.6.2025 klo 23.30 Yhdysvaltain lääkeviranomainen FDA hyväksyi kolmannen käyttöaiheen darolutamidille edennyttä eturauhassyöpää sairastavien potilaiden hoidossa Darolutamidi on ensimmäinen ja ainoa androgeenireseptorin …
Outset Medical Appoints Renee Gaeta as Chief Financial Officer
GlobeNewswire
·
June 3, 2025
SAN JOSE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of Renee …
U.S. FDA approves third indication of darolutamide for patients with advanced prostate cancer
GlobeNewswire
·
June 3, 2025
ORION CORPORATION PRESS RELEASE 3 JUNE 2025 at 23.30 EEST U.S. FDA approves third indication of darolutamide for patients with advanced prostate cancer Darolutamide is the first and only in the U.S. and FDA-approved androgen receptor inhibitor ( …
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
June 3, 2025
SAN FRANCISCO, June 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for …
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
June 3, 2025
WALTHAM, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, …
MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025
GlobeNewswire
·
June 3, 2025
ROCKVILLE, MD, June 03, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today …
CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT
GlobeNewswire
·
June 3, 2025
KUALA LUMPUR, MALAYSIA, June 03, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company that develops innovative cancer medicine, today announced that it has received …
Jushi Holdings Inc. Announces Voting Results of Annual Shareholders’ Meeting
GlobeNewswire
·
June 3, 2025
BOCA RATON, Fla., June 03, 2025 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Corporation”) (CSE: JUSH) (OTCQX: JUSHF), a vertically integrated, multi-state cannabis operator, announced the voting results of the annual general meeting (the “ …
Fortrea to Present at the Jefferies Global Healthcare Conference
GlobeNewswire
·
June 3, 2025
DURHAM, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that Chairman and Interim Chief Executive Officer, Peter M. Neupert and Chief Financial Officer, Jill McConnell …